Global Health Developments: COVID Vaccines, Nicotine Pouches, and Cancer Drugs
The latest health news includes Pfizer's updated COVID vaccine showing better efficacy, the FDA fast-tracking nicotine pouch reviews, Philips facing investigation over sleep apnea recalls, and WHO urging the Taliban to lift female aid worker restrictions. Summit Therapeutics and Eli Lilly report mixed outcomes in drug trials.
In a dynamic shift in COVID-19 vaccine development, Pfizer and BioNTech have announced promising data showing increased immune response from their updated vaccine in older adults and those with underlying health risks. The ongoing trial reveals a significant rise in LP.8.1-neutralizing antibodies after the updated dose.
Responding to mounting pressure from the Trump administration, the FDA is expediting the review process for nicotine pouches from major tobacco firms. The goal is to complete reviews of products from companies like Philip Morris and Altria by December, a move signaling regulatory agility in the nicotine product landscape.
Paris prosecutors have launched a criminal investigation into Philips following a global recall of their sleep apnea devices. The investigation scrutinizes potential charges including aggravated fraud, as the devices were recalled due to foam degradation leading to severe health issues.
(With inputs from agencies.)
- READ MORE ON:
- Pfizer
- COVID-19
- immune response
- nicotine pouches
- FDA
- Philips
- sleep apnea
- WHO
- Taliban
- drug trials
Google News